RecruitingCOVID -19COVID - 19COVID 19
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Eligible age
18–79 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
You may qualify if…
- ✓ 1. 18-79 years old
- ✓ 2. Have a history of any of the following risk factors for severe COVID:
- ✓ Current:
- ✓ Age \> 65 years old
- ✓ Physical inactivity (defined as \<150 mins of moderate activity per week or \<75 mins of vigorous activity per week)
- ✓ HIV with CD4 count ≥ 500 cells/ul
- ✓ Smoker
- ✓ Obesity with BMI ≥ 30 and \< 40
You may not qualify if…
- ✕ 1. History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
- ✕ 2. Received a COVID-19 vaccine in the last 3 months.
- ✕ 3. Tested positive for COVID-19 in the past 3 months.
- ✕ \- Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit.
- ✕ 4. Active use of immune modulating medications.
- ✕ \- Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function.
- ✕ 5. Diagnosed with immunocompromised stated.
- ✕ \- Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen).
Where it's recruiting
Maryland
Bethesda
Source: ClinicalTrials.gov · NCT07287137 · last updated 2026-11-02